Junko Matsuzaki to Antigens, Neoplasm
This is a "connection" page, showing publications Junko Matsuzaki has written about Antigens, Neoplasm.
Connection Strength
2.654
-
A rare population of tumor antigen-specific CD4+CD8+ double-positive aß T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells. J Immunother Cancer. 2019 01 09; 7(1):7.
Score: 0.582
-
Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells. Cancer Immunol Res. 2014 Apr; 2(4):341-50.
Score: 0.409
-
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010 Apr 27; 107(17):7875-80.
Score: 0.317
-
Sublethal Radiation Affects Antigen Processing and Presentation Genes to Enhance Immunogenicity of Cancer Cells. Int J Mol Sci. 2020 Apr 07; 21(7).
Score: 0.158
-
NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol. 2017 06; 145(3):420-425.
Score: 0.129
-
HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. Gynecol Oncol. 2016 07; 142(1):158-162.
Score: 0.120
-
Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016 Mar 15; 7(11):12840-56.
Score: 0.120
-
Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Sci Rep. 2015 Oct 08; 5:14896.
Score: 0.116
-
Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS One. 2014; 9(8):e104099.
Score: 0.107
-
Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res. 2014 Jan; 2(1):37-49.
Score: 0.103
-
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A. 2012 Apr 10; 109(15):5797-802.
Score: 0.091
-
Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells. J Immunol. 2012 Apr 15; 188(8):3851-8.
Score: 0.091
-
Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors. PLoS One. 2011; 6(8):e23651.
Score: 0.087
-
Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. J Immunol. 2011 Jan 15; 186(2):1218-27.
Score: 0.083
-
Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction. Cancer Immunol Immunother. 2022 Dec; 71(12):2881-2898.
Score: 0.046
-
Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy. Cancer Immunol Res. 2018 05; 6(5):594-604.
Score: 0.034
-
NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. Clin Cancer Res. 2018 03 01; 24(5):1019-1029.
Score: 0.033
-
Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015; 10(3):237-46.
Score: 0.028